Figure 1.
Overview of DFCI AYA ALL Treatment protocols. (A) Earlier patients were enrolled on parallel pediatric 00-001 (2000-2004) and adult 01-175 (2002-2008) trials while later patients were enrolled on parallel pediatric 05-001 (2005-2011) and adult 06-254 (2007-2011) trials. (B) Breakdown of patients according to treatment protocol, age, and asparaginase formulation. 1Intention-to-treat postinduction asparaginase formulation. Patients who did not receive postinduction asparaginase are excluded from this table. 2Cumulative incidence (death included as competing risk). CNS , central nervous system; Dx, diagnosis; Fx, fracture.

Overview of DFCI AYA ALL Treatment protocols. (A) Earlier patients were enrolled on parallel pediatric 00-001 (2000-2004) and adult 01-175 (2002-2008) trials while later patients were enrolled on parallel pediatric 05-001 (2005-2011) and adult 06-254 (2007-2011) trials. (B) Breakdown of patients according to treatment protocol, age, and asparaginase formulation. 1Intention-to-treat postinduction asparaginase formulation. Patients who did not receive postinduction asparaginase are excluded from this table. 2Cumulative incidence (death included as competing risk). CNS , central nervous system; Dx, diagnosis; Fx, fracture.

Close Modal

or Create an Account

Close Modal
Close Modal